Return to CBI Antibody Core Home Page
  Return to biothreat/emerging pathogens list
    Return to malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum ) list


malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum )
PFE1120w



Western result: +
GST
GST-PFE1120w
(fragment)

N.A. kDa (recombinant)
The western blot contains a test lane of ~20ug of a total protein extract from E coli with ~50ng to 500ng of the antigen (GST-antigen fusion protein). The negative control lane is the same except it contains ~50ng to 100 ng of a GST fusion protein of an irrelevant antigen. The blot was probed with a final antisera dilution of 1:1,000. The secondary antibody (Rabbit anti-mouse IgG + IgM, (H+L) horseradish peroxidase conjugated (Pierce)) is used at 1:5,000 dilution. Note, the molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used and it is fused to GST.

Antibody Name/Abbreviation: PFE1120w
CBI Antibody Core Code: A0468

"Lot" Number: 1 Position: 100(798-897)
% Identical Homology of Target to Mouse Protein: 47% (NP_033975.1| CD22 antigen)
Molecular Weight of fusion protein: N.A. KDa

Target sequence used to make this antibody:
YNEISHKCMNPYDIHPHNFNEEYLLEQNFITQNIQNGHNY
NKDINDKNYKDNFNQNYDYEKSKKNYKGSILNSLGKNTNN
IDIHHEVNNNLPSDIMRSNS






Sequence Name: PFE1120w
Full name:
UniGene Number: N.A.
Accession Number: PFE1120w
Source organism: malaria parasite (malaria (P. falciparum)) ( Plasmodium falciparum )
Full length size (aa): 9341
NCBI information page: click here

Full length sequence:
MIKNIVNQFIKIYGQEYLGEWDAIQNLTINSVTSPEIILKNVPFPEKFFE
LADLPLEIIYSNIKNVRIKFLWSSIFSSNISPINIYANDIFLVVKFSYPS
IWNTNKTLNTQYEVKKKKLRKWDSVNISKEKKEENFLKALPIKLINSLRI
FAENIKIIFFDNHIHTKPFTLEFFVKSFKIDELSKYKLKLNEEEKKNIKK
NLLINIWIRLIGIHMIYKEYRKKIKYNKRVKKENEEKGCKRDNSKEKHDK
SQNKSETVQGKICYICIYIYIYISNVLLVTIFYIIIYEMFLTAIEKLFSE
STNSLKEPLKIHLKNSQSKILHKTRNGKYCSFSDYEMNERIKVGSLRKKK
RKKEIDIMKKKEKIKNIYKKGYSDGSSFKKEERYYFDIPKNNTGFRITPK
EGIELHVIFKKHDIKALNELKEDIKYFKNVEMCILRHNKEYSSEHHLNNT
PRDEMYVKKSCNCYNISKQVSMDENNKYNINIEHNDNNIENFENNNSNSN
SNSNNYYMNNNFPVYNDPKQHNVNNINNEIISIDYDLIIENGFKNDVPPT
FNNISNYENLEINFTSECFNAFFNFIKYIEFYYLYKGGCTKIFNIVPSIE
ECIKYSEYRKTFNQKNSKMNDEYAEEFMNKFEASCPIHLLTKLRLLSDER
IYSKEYFNNIQKGEWKKLFYNFIKNKKGKNYMIDENLEKLDRWFTHDMLF
NLVLPQINFTYIPLNLNHYNNNKIYYNKCFLSYNISCSFLFKQEKLSSMK
KRYAIYMHNFNIHSLFVLFKRNKKFLINKKFCPIYLIEKLGIKNHCVYNE
ISHKCMNPYDIHPHNFNEEYLLEQNFITQNIQNGHNYNKDINDKNYKDNF
NQNYDYEKSKKNYKGSILNSLGKNTNNIDIHHEVNNNLPSDIMRSNSTCS
NYKIHYEHNYNNIEHYDNTVNYKENKKCSHIITTKEKEAYMRSAGQRGRN
HLFYNEYYNNTTKGRYKNMYMNNLNYNKYNDNNCDNNCDNNCDHYCDNNC
DNNNYYYEKDYMCHIFFNNDNKVNDNMQYKYIDGNIDTNNVDKKKIPIEN
LQSFKNEYISQKHNMNKNKMIHENDINYNKNNVDSKTDDKKGFWKFILGK
KYKGEDDSIKNNKSNYNTILGTNFDLLIYNKINKLPNCTMIFINDYSNNI
REMDIYICKYIININNLIPIMNFIPKNNICLEIFLKYDNIIDKDVIEALT
LYLSMGSARKKIVQVCIEQLKTYFIHSSYLYKELVNIKSYLNKIKKKKLV
GTMYSREIFIEHSILMDPFKSKMDEKEKVQDKQKTRKNFGNKKLKDSIQN
KNFYRSPNINNMKEVKNHNVNIEKNIKKGRHTNDNHFGDQISSALEHKRY
DKDDNNVENVININNHNNILCKNKQIIKFAENEESNALNIHNLILNNLFV
PQKNVYHIKKNNSFLLYKGKRKKSNFLYSMRNSYYTFLKKYMEYNNYMHK
VKNTSLLSIGFCFQLKNIFLFHDKEDSLFYLHSKYIKLEHLFNPCFNNNK
HNNSVVACNRFEFRESSNDKTSHSNNSKKIYKEEKKKYSDYIDGKNMYPM
NIDQTVKNKELLLYIKSLKLKKNNNVYSLRIDIVNCNLNEVCISLLSVYK
YMIPYDHLELIKIRLKKYYRIKQFLIDNNKNTSHLRKFNITNKLLYMILD
NFFYKNHMIGEKNQMMIHNKKYDDNMNIVKANKNYERYIKNLVIKILDHE
KILYNKEDFEEIFYMIVRRNAYNQQRFDSLYFKENDILKKNSIRNDKNKY
ILDSTEDTFSFNTMERNSADYLSNEKCNKYNSSINDISINDSSINNNSIN
NISINNSSINNISINNDRMNNDSIYINSLNNYSHLIDREYNSSIDNTFIS
NNDYYNVNSYSYKYSENYYSDIDKYSNCTYNYNGEKEEILIKERNKIIDN
EEKEDTQKIKKYIDMKMDRINIIKHANKEFYQNCNYLNLIDLFIFEHINY
DDETINEEDLFFINNNNNNNNNNNDNNNNNNNNNVCSEDIITQMDTLNSK
NNIKEKIYFLLIEKTNISINNRNEGMFKFVLNNFMSEICRLYNGINISMK
IQSFYIFYILKICKKRYNVKYVTDKKNHKIHVRNDKEGYFELPKETKGNE
EKKKKNYNIIKTCKKYIILTDTVSNLFSVSKCNMKKKKSKKNSFFFDNNI
CILSKRKFDLYIDDYHMNYKNMKPQIHLDIHINKWTNEKIIKISLSNFYF
FYSSTLFILFSNVVINYILTYIQEKQKLNILLFQYDNFRSAISSKYTNPH
LENKGYTYDKNKSYTSIDKYTLHFLSRNKLKKIKLYNDKFVSIEQIDNIC
DSSEHSILDDNNDEEIDMRNKGIAQNSNNNENNICKKEKTKEIKDINGDY
TGVSDNTFYYDMYENEKYREKRKKNSKHYYDYNTYKSVGEDNPIKELLNE
KINEQINNNGLYNKLYYHDNMTSSFEKQNTFDKNFNTYISRNRNKKTIIN
NNNIIHGSIMKNNSYSEGNTNKSEYEYKYEYELNEKNKMDKEEYIKNHKQ
TNDCTKYNINKDGYPKENSYETFRKFSNSCYDLKLYGNKHDNLSNRENDN
ISSQKEEKKKHSIQKYPKLYKAKNKRKKSDHIERLNDIPNAIKSDTKKFP
SYNNIYSKRKMKKMYDNKMNNKNINNNNNNNIINDNIMNDNRNKNSSDNI
DSNNYKKDIKIFISSENVNICYLVNYHRFKYIYKKNFNIDTYMNDYINLI
DSCSNFCDKNENENSDNHEHVGIINKDLYNVNLNFLFKLDYMCIEDKQKS
IMAFFPFFYIMLMKNCNYVISHLTVVDIKYNSQYFIKEKKKKEENRKNNN
DVENNMRAKCNRHLSNYMNSILNNSADNKHNNLDKEREKEPIFMNPYEDK
DKTKDDVEHSINSNQIRYVGNVKCIGNNNKHKYVIPFKSNVKNKMEGISS
SSDSCIYKKTKRKKYIDDIDCNNINDKNKKSYDILYGNNSQEYYENIKNL
RNYLKNDMIKNVKKSSEHKSIDGNANNLYDIPPNDNEMKDEFLIKNDDDN
KMNSMCVDKDDYKQRSYISYLLNYKKKNGENKYSTKNNIMKRFNSLIHFI
GIHNNTSKGASKKIKGIKRSLSLFSFKSLPIRRRKFGKWNSNTIDVFQVG
QENNYKKNKKKTKKFFGLFNTDNNDNNKSLNDNIDYNKNNSGLNKERNNN
LDYDKNGKYEKVSYDEHKNISFTHSDNRNACIINKNNTEKNLKMNYDTLS
GDNNIKKNKKNRWKLSSCTVSIFNINLFNCIYLKKYKKHGEIYLQPLIYN
YKNSNILNTIYEKSDIYENNSFNINYFDINNNLKHMNYKNIVSNYYIIEN
EFTLIEYINQLYNLEWFNKFNLHHLYNVNRIQSNFSNFMKLNKRKGSIVC
CYVPVFYKNISLTYRNIYKCLLINKYMESIPYLSKLYKNEHMCKYLFGNK
NKHNLNDNYIKEYILHLLKKKQSEKEQYEQKYSFELKKDIFKDMKNDDRT
QNKINKNIIKEKRDYYNNSNINIINMKYHKNDNNNNNNNNNNNYNNNNNK
NNYNNNNKKNYSYSNIPKELSNDLKEKGNKKYYQLFQSQIVQNIFNYRNK
NKHNNNVDNIENVMQNEVIKDDVKPLNVSCSLYDNSNLSSYPFHIYNNNN
NNNNGNCNSNSNNCNSLNNYLIYKKDFISYNLWKQNHIYISLKKEVSYEM
LKKKQNKKKKCTNEGFHFYIHFYSSSLNMDPYFLSTINFYFLNNLNKNLI
LCDIKETKAYFLHKYKNIRCYYNHTMGIDEHNNDLMNKHNMNVNNNNNNN
NSEIYGHIKYGRNDIYERPSIRKNKYGKKKGYTSKYADNNNNICNNIEVQ
KSHNKKEECFGQTPFTKQDKLYNFMNRLNNICEKIIGKLETKKNFIINLD
ISNIDINILDCSYIYDSKYLYVDHVHPYYNNQYIYVSMEQYENIKKNSGN
YYNEFFKYEEIDHKSFSNDFNYLIYNAFTNYSYNNSFYIISINPNSVKRM
SIKMSSTIICNNINKELNFHDVLSIFVHTFKMKFSKLKTNYMKNRAIQSK
NYMHKLLEELYNDKDDYCHKIHKRERTKSKTKKNSRRNINNNANKHTYTT
INNNRTSDSISNFNYSYDKENDNNHISHLNNNIFNTLSNESSAQDNINNT
YSSLSKQNNKNMINHYDMIINSSKSNEDTNHCRRYPSSSLSNYDESTSCA
STSSIFASSLNSVLFYNSQERYNNNNNYNKNNPEGIGNTGKRYESMNEYN
YNMLHKINKRYKYWNEERIYYEKSKSFSDSIYTKESLCQKKQKKNNYINM
YNEPFMNIHNSLSNDYNDIMKSTIKNDHDRKIRKNIKRQFYKFIKKVYKN
ILSQNRRNKLILNNIVQDNKWIINLENFVCFIPSFQRGFKLSLYLNKLII
YDYNKINICNNISPFRLFIKNNASKKYLQLCNKILNIYEYLYIRKILLKG
NGKGKRKIILENLKNQIYNNQFYLIAYENMKNINFHIDLKNTRFTIHNKT
TMDLINFSVELWNSFYSYLYVYTILPEVSSSSFCYLNSCINVDNFQKGLL
LYNNILRNYISMCKNGKNENVPYLHRKGYSLDDTHINNDKNNNNNILIRD
DNNYDNHNDIDNNIIKKEDSKTCSILKHHRNNTQSEYDKYEESDCCDNSY
NKKSLIILDNNTTSKFSNNEQTNFSNIENEKKENDKLEDMVGNSNTLDYY
VDKLFYYKNKINYKYLIINKFEFHTAGINISLKELNDKNYYFLAFVNNNL
LFFLYFYSKYKTILDYVSNENVFNLTTNYIYPIEKVKFSKEGKYSHYYMS
GHLEKYRTNTNGYRKDTIRLSTISMLKKKRKRKKKKMKRLSNHRIINNYD
KEKIYINNDDNILPKKKNKKFVNMKKGSLHMDNMNKLNKENNNNNNNNNN
NNNNNNNNNNNATSNINHFVDFKENNEQIETNSICSIKFQKTKTSVFSFT
NENNNKDDKDMTQERRVNNGLSKKIKTTIQKFFTRKLSQTLLLSNKKKEK
KKQKKDDHSLGSLNSIYFNHKKKKPFLKQHDKYKNNITHEKYLCLKNKEA
YFNKTINFNMKINLLETWFIQDDLFMYNNQENINKNIKMSYFLKKSRKKK
NNNEVMKKKYTNKDTYEGIKTISEEMDNSHRDERKKQASSIDTEVGEIMK
VVKKLRIKSLSSSNSSNNLNILKLLCKSKIYNNTFMDKKIRKQIFYLAKR
KRSMNDEVLDEECIKKMNLNKYSLKNTYKGKKRITLDMDKIEMESEDLNR
SKMVSQIDSNNNFMSNEGNDPNNNYDNEHDLDDDDDDDDNDDDSLCYLLK
DPNRDDNTYDNNYDNDLYIHRKNHVQKNFENELFDTIIDNEKSYRRRKKY
FKLKQMEERKRKKEQERKRKKKENLKENKRNVCLSIIFSININHKEKKNE
HLFYLESEVNNFNIMLGKCYSFNEIYDKLKLFKGKTNMKSSINDSIIFDL
NYMNRNIDYIKSRSSFYTIRNNNDNINNINNININSINNNNDKEQLKKEL
EYLFYDNSNFYDIYYNEMKQTERLKIMLCNKKLKKERKNEIKKDKKKMCI
NNKNDYNNKSYDNDNEKKRTRKKKYINIKNKKNKKDIVNKNMFYRNNLIY
NTNEEFNESNRHSIYYSNGKNINSSNILFLLTYKTKVLYEDKYNIFLNEN
NNIFMPNIKEENEWFLNMNNIYFMIKSREVKKSYKIIFKELLINITIDNI
KELYKLYNNFRYNIYFASFYKNYFSFFKNIYIHPFKNKNQSLLKKSSEKL
EIQNIYLRNMHKFKMLKNHIIYNKLKQMSKNKIYRINKNKYIYQQEIEGN
KKFSFQMNKNKYIHKNNNCDIYYSDNENDNLDIISSNQNDRHYKYVNRNK
MKKRRNVQNNKIGKDKKNKSKDTEREKLIYSIKNTKKLENIESQKCTNKD
NKILYTSFSNKNEIFNVQDKYTYKERKHIKDISKKGNEKMKGNLYNLIKR
KTIYEHNWEENQYNYNNINTLYYARRRFLISNMNIYKKMVDSYIKIQPLI
NLENTNRKYFEIIYNIKEKYTEIELYKENLYNLYNQIFLIINNINNEKNI
ICHGLIFLKLLNCFYPYNNNYIRNLLYYLFVFSKYNKFAYYLCNIKKYFH
YNYFLTFTKILHTNDIWNDIHINQKTNNNSKAFYKTSQEYYSLQKDTKHV
PIILNTNQRINENISIHKEITENFKKEGMFKENSFNKDKNNITFFLIKFL
LYFYHPYKLKYEKGKRKIIKKTNYMNKQIRGGEKKKGRTKKEYGGMLNND
DCVSLLKRINLKNYRKKRNKSKKQLLKQAIENWSDANILNDFNYKNKKEN
IDNYNYNEYMITNSELSCQKSYYDKNSIKKKSIYSINSNDNLKCNIINCL
EDIYLNNKSEKLLDQKKEFYDFNKKEKKIKINVDIHNICLKIHQLNKENI
LTLNVYDLNYYLFTCLYKYEFLFFNKNECVRFYLNEKLQHMKFEDLYKDN
KMNECAKNVISNRYTDNEWYDISYSNSSISNNDNNYYETCRDEDNNIKKP
NYIKMNLTFKIGLRTYDNMYNIQDNIINPTTINFYIKEKFKYFPILNIHF
YTTSININITTSFLYLYQYLFANLNFKKEFNEVKNSKIEIYNDLHSEIII
FYKTRTKNNNYIWKLVIINKNEYHEFPCECLYFCINKKKEKNTINSEFQG
MNRNSEDYIITNENDLNNLFKNISKIGFKKQNIYNLVSKHEKHLLYDNTQ
SVYDILYQFTYKMPFLYKNYDNDNKIINIIKKKSSWIYIGVLYTDDLYSR
AYKIPNVRILRHYVKYNLLVEPEIVRNKWCLCIGTCIQIENNTGLYFRIY
KEGKTNYFSRVNFKWYKRKKNKSNSNYSMWEKGTKKGSHESSKSRNDIMK
IKSYNRNFISYMDKLKKKKKRKEKKIKDKDYINILPFSKRAIPIFWLYDC
TLPYIKILRKKEKKRHSKNLRNSYNDERLDIEAVPFNILYKLLNKYALNN
NNLYQKKLDISPFELTFKSLIMFHCYVKVKDVPTQHIKETSYNYSIVIEP
MVTIKNNLPNPITVIVRLKKDKNIFNLSKRKYDNKVEDKIFYNSHNNNFN
NNIDNIDNNNNNNNNYYYNYYFNHYSNYEMNDDITKILKKQEMFALVPPH
HYWSLPICSQAFYMKIFYHGLQIEKMNFICDYMNELTNYFDYKHVKLPDM
NEHPLFTSKFVNSINEEQNQNRNRKDNYMNNMDNNENIIHQKRSDQHLFD
EIIKNDNNNNIKCKYSNNHVDNDYYYNDRNRNINYWAYKYSLESHKKNNS
VFLYNDIIKQIQKDEMLDQNNFRHKTNKYNNYPFNNKSSFCRINRKNSNN
YNNNDDNNNNDSNDNDSNDYDSDYYFCSKKKKKMMDTNNFLYVSEGFFPI
YMPTTDTITTTKILNHKYGLIGDIFSYEELKFIYFENKVNQMNRKVYDNL
YIFKSITMSADVSRRRIDFYFPFFFENTTNVCLYVNNKLLPPNSRLYMTE
EEAKNVKIKSYKHDNMNNKILCSNVSSKIDCTKTNMIRPLINLVYRKINR
KQKVRFWEKYEERKKKNVKDNNNSIDYNANVDVISLKNEQMEMRNLNGFN
DKKKDIETMNNEEIHIEEKHRTTDNINYLKSCEVKQNTEKENHELIQKLN
NYQNKKLEKKMNDSILSVNLCESVDSTTNRNDSYHANSSKYTEMLLNTSE
NSHNKIDKVKSHKARKNVFKYLLRNERLLFKRRRMNNNKNKVKKYKKANK
KNNNMDDDYNNDNNNNNNNNNNNIIIRRSRRKGLRAFDNIKIMKRFRLFN
KTIQSSKLKEHEDELERFDDTEGEEMEDQEFEEHYDENNDENDVYNDDYN
DEYNYDDNNDDYHNDVHIHNDQPPELNRSINSSPHYEDDDNLITEMRKEK
NKKDKKNEKGKMKNYIFNRNSYTLNKKDKKKISSNKKKGISKRDSNQFSK
KFNYDIMNIYNEEDVINDIENDQEISDERADMEASHKSKKSKLFKNNSIL
SLNINKKRKKKITIKNSAKRKNNKNIKYGLKMKFSINPFFINTTEKKKKY
NEEEENNYDENNINNSDNFNSSEKLTDSSNSKQSEKNGIEFISANDGYMI
DKKLSQFDEKELNTNKNIRSIEKNNYITNHVDEKIENEDDPVNDKEENHN
EHKKEDVSNKEKKEMLYKYSSKKKSKERRKIKINTKDSNEGGYLSLGICV
RYAEEPFNKSKIVTFVNSYIFINRLPFDIKIVTDSVRKKSETFFISQNVN
KLEINDTYKNLFQLERKKLNEHKCNNISSIQPLIEENETFFEKQFNNSNS
LGKENSSNYEKSINQNRDEESCKMNTSNIENNIINNNKNTDIYNLGNDNY
KNNNEHDIYHINNDHNISKSNSLNKHNSSINGNITYVEKNVSDNNVKKDS
SKYELNEENKDNIKNEGDEKGGKNKSNETYIRKGEIVSFHYHRNHIRIKD
SENKYSSLPFSLIPKNVPSNFQIELFNVNKSQINNTNNLLVEINICSGIF
GDKQQLPYTYNGYFYILSLPVRPQFEIINATKFIIAYATDINKYTKRYMN
SSNYNTYLNRYNKDGDYSVKMIYPYSSIYYTLRHNNEIESSKIALKIVGV
QKSSWCINTINSFIDNVVILPYRIYGDNLLSRKTKRNTKNEIFKDDMSQM
SYQINDSSSDKLSSKSDSINSNNMERYINDDEENDNLFLGHNLINKKLYS
FLIIRDNGSRAIVITEKYNLARKIVRTKNFSKIHKLIALNSRKKILLSQK
NNNKKYILNRNMKNFIYFNFPNVPIIYKFNIPRITFTWIHRQDVIIAIHL
TQLKYNGHIYPKEIVNNDITEMFTPINILKKKELNEYVQFVFLNSYINSI
FLIEQIHIDHFVKGDIPVILKSTNIEEDEKENIFLYIHIKQYCVDSLKQA
PIYQSITIKISPLNANIELLVIEQLIEIIEKEKQLLLLYEKNDKSLPPLV
STSKTAKSAINTTLKIYSDRNFLQMLYMDEYIKHKMGHDVSEQNIEIENN
RLINSVNRIDNTSYKMIGHKKRVDNIYNDINNMNIKPNAYSYYFSSTKAR
MIKHNKIININNISPNIFSDDSTKSSNSSKSSHKNKQYILEKKICKLLLG
YYKYKKIHNLINNTFYNINNINDELLLPIKIQYFKNRKIFMNAFSSHLFL
HPNPRWIDNKSKPVYIREFKIHPIEIIASIRTSEHRISRRVLHIVDALPL
DTPSMRIRLISQKRNYIVCTWDGLFQSLRISYFRQLLRQSLPSAWLSNPF
AIIKGFIKGLCALYKESVRGVKTSSNFFDGFMSGFKCGIIILVVNTVGGL
FQSLSHMLNVCHKLMGGSRPRPPSILDSIILGLDGLILDTFYRPWVSLVT
QPIISINKGNSTFKTTCIIIGCILRCIFSPVFGLLNFSASITEGFANTLI
GDFERFSRVQERAEFETEKIHKSNTTFKKGKTLKKVGKKKV





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.